Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.63 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.55 |
| ▸ | GABRP | O00591 | 1/20 | 0.53 |
| ▸ | GABRD | O14764 | 1/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.53 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.53 |
| ▸ | GABRE | P78334 | 1/20 | 0.53 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.53 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.53 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.53 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.53 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2006696 | 1.00 | HTR6 (0.63) | HTR6GPR84GABRPGABRDGABRA1 | |
| SCHEMBL2006693 | 1.00 | HTR6 (0.63) | HTR6GPR84GABRPGABRDGABRA1 | |
| SCHEMBL858092 | 0.81 | GPR84 (0.63) | HTR6GPR84METHTR2ADRD2 | |
| SCHEMBL1177649 | 0.81 | GPR84 (0.51) | HTR6GPR84METHTR2ADRD2 | |
| SCHEMBL7940911 | 0.78 | HTR6 (0.63) | HTR6GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL2012387 | 0.78 | HTR6 (0.63) | HTR6GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL2012385 | 0.78 | HTR6 (0.63) | HTR6GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL1445683 | 0.77 | HTR6 (1.00) | HTR6GPR84GABRPGABRDGABRA1 | |
| SCHEMBL30675329 | 0.77 | HTR6 (1.00) | HTR6GPR84GABRPGABRDGABRA1 | |
| SCHEMBL31403 | 0.77 | HTR6 (1.00) | HTR6GPR84GABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252930-B2 | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. (NL) | 2012-08-28 | — | — | US | disclosed |
| US-8252930-B2 | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. (NL) | 2012-08-28 | — | — | US | disclosed |
| US-8252930-B2 | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. (NL) | 2012-08-28 | — | — | US | disclosed |
| EP-2041131-B1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYLCHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2011-09-28 | — | — | EP | disclosed |
| EP-2041131-B1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYLCHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2011-09-28 | — | — | EP | disclosed |
| US-7964728-B2 | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-06-21 | — | — | US | disclosed |
| US-7964728-B2 | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-06-21 | — | — | US | disclosed |
| US-7964728-B2 | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-06-21 | — | — | US | disclosed |
| US-20110053962-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2011-03-03 | — | — | US | disclosed |
| US-20110053962-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2011-03-03 | — | — | US | disclosed |
| US-20110053962-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2011-03-03 | — | — | US | disclosed |
| EP-2041131-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYLCHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | Solvay Pharmaceuticals B.V. (NL) | 2009-04-01 | — | — | EP | disclosed |
| US-20080009514-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | ABBVIE B.V. (NL) | 2008-01-10 | — | — | US | disclosed |
| US-20080009514-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | ABBVIE B.V. (NL) | 2008-01-10 | — | — | US | disclosed |
| US-20080009514-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | ABBVIE B.V. (NL) | 2008-01-10 | — | — | US | disclosed |
| WO-2008003736-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYLCHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008003736-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYLCHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009514-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | CHRNA5, CHRNA7, CHRNA2 | HTR6 70/4885GPR84 248/4885GABRP 358/4885 |
| US-20110053962-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | CHRNA5, CHRNA7, CHRNA2 | HTR6 74/4885GPR84 262/4885GABRP 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.